Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Sipos

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|October 16, 2025
The Diagnostic Potential of Urinary Titin Fragment in Neuromuscular DiseasesAndrea Sipos, Dávid Varga, Endre Pál
Acta Haematologica|April 26, 2003
Homogeneous immunoglobulins following allogeneic bone marrow transplantationMelinda Hajdu, Eva Puskás, Andrea Sipos, et al.
Neurology International|August 27, 2025
Measuring Myotonia: Normative Values and Comparison with Myotonic Dystrophy Type 1Andrea Sipos, Milán Árvai, Dávid Varga, et al.
Muscle & Nerve|June 9, 2023
Urinary titin in myotonic dystrophy type 1Dávid Varga, Brigitta Perecz, Krisztina Fülöp, et al.
Orvosi Hetilap|July 10, 2003
[Methods of screening for adult celiac disease in patients attending ambulatory care service in immunology]Katalin Kilián, Kata Miklós, Katalin Rajczy, et al.
Neurology International|May 26, 2026
Hungarian Validation of the Individualized Neuromuscular Quality-of-Life Questionnaire (INQoL) in Adult Patients with Muscular DiseasesBrigitta Ruszin-Perecz, Réka Héjas, Alexandra Makai, et al.
Neurology International|August 27, 2025
Elevated Urinary Titin in Adult Spinal Muscular Atrophy: A Multicenter, Cross-Sectional Observational StudyAndrea Sipos, Emese Rebeka Ripszám, Judit Mária Molnár, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative diseaseHajnalka Andrikovics, Nora Meggyesi, Aniko Szilvasi, et al.
Haematologica|June 5, 2014
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutationsHajnalka Andrikovics, Tunde Krahling, Katalin Balassa, et al.
Orvosi Hetilap|March 9, 2007
[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection]Hajnalka Andrikovics, Anikó Szilvási, Nóra Meggyesi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|October 16, 2025
The Diagnostic Potential of Urinary Titin Fragment in Neuromuscular DiseasesAndrea Sipos, Dávid Varga, Endre Pál
Acta Haematologica|April 26, 2003
Homogeneous immunoglobulins following allogeneic bone marrow transplantationMelinda Hajdu, Eva Puskás, Andrea Sipos, et al.
Neurology International|August 27, 2025
Measuring Myotonia: Normative Values and Comparison with Myotonic Dystrophy Type 1Andrea Sipos, Milán Árvai, Dávid Varga, et al.
Muscle & Nerve|June 9, 2023
Urinary titin in myotonic dystrophy type 1Dávid Varga, Brigitta Perecz, Krisztina Fülöp, et al.
Orvosi Hetilap|July 10, 2003
[Methods of screening for adult celiac disease in patients attending ambulatory care service in immunology]Katalin Kilián, Kata Miklós, Katalin Rajczy, et al.
Neurology International|May 26, 2026
Hungarian Validation of the Individualized Neuromuscular Quality-of-Life Questionnaire (INQoL) in Adult Patients with Muscular DiseasesBrigitta Ruszin-Perecz, Réka Héjas, Alexandra Makai, et al.
Neurology International|August 27, 2025
Elevated Urinary Titin in Adult Spinal Muscular Atrophy: A Multicenter, Cross-Sectional Observational StudyAndrea Sipos, Emese Rebeka Ripszám, Judit Mária Molnár, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative diseaseHajnalka Andrikovics, Nora Meggyesi, Aniko Szilvasi, et al.
Haematologica|June 5, 2014
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutationsHajnalka Andrikovics, Tunde Krahling, Katalin Balassa, et al.
Orvosi Hetilap|March 9, 2007
[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection]Hajnalka Andrikovics, Anikó Szilvási, Nóra Meggyesi, et al.
Pageof 2